Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan Development forecasts for 2013-2015

Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan

Development forecasts for 2013-2015

This publication is a compilation of all vital data and analysis concerning the markets for generic and innovative medicines in the CIS region: Russia, Ukraine and Kazakhstan.

 

It explains the effects of continuing legal changes on market conditions and details the implications of reimbursement procedures, pricing, data exclusivity and the expiration of drug patents.

 

The report also features informative profiles of the leading manufacturers of generic and innovative medicines in CIS countries and discussion of the prevention and enforcement procedures used by each country in response to counterfeit products, along with complete market forecasts for the period 2013-2015.

 

Subjects studied within this report include

  • Size data of each market segment in the CIS region: generic drugs and innovative drugs - for each year from 2009 to 2015.
  • Market share of each of the two segments in Russia, Ukraine and Kazakhstan
  • Regulations in each country that govern pricing and reimbursement
  • In-depth market development forecasts for the period 2013-2015 – for each segment in each country
  • Applicable VAT rates for various types of generic and innovative medicines
  • Price mark ups for applicable medicines (average and official)
  • Reimbursement structures in each of the CIS countries
  • Attributes of commonly used systems for reimbursement for generic and innovative drugs in CIS countries
  • Changing drug reimbursement lists: the latest adjustments and expected future modifications
  • Impact of reimbursement policy changes on the overall generic and innovative markets
  • Periods of data exclusivity and patent expirations for generic and innovative drugs in CIS countries
  • Innovative and generic medicines generating the highest sales
  • Profiles of the most prolific companies manufacturing generic and innovative drugs in each country and across the region
  • The counterfeit market – shares of overall sales and regulations in place in each of the covered countries: Russia, Ukraine and Kazakhstan.

 

These convenient features make the report useful in everyday operations

  • Comparative analysis of vital data and current market conditions in each of the CIS countries
  • Analysis of generic/innovative drug pricing policies and reimbursement schemes in each CIS country
  • Complete, insightful forecasts for the market to 2015
  • Well-researched industry intelligence obtained from a wide range of sources and assembled into one reasonably priced resource.

 

Learn about specific issues and their impact on the market

  • Progress of the Ukrainian reimbursement structure, initiated in 2012
  • Russia’s Pharma 2020 programme and its regulations on foreign generic/innovative drug producers aimed at strengthening the domestic pharmaceutical industry
  • Progress on the integration of GMP (Good Manufacturing Practice) in Kazakhstan.

 

This report answers your questions about the generic/innovative drug market in CIS, including

  • What are the specific values of the market for generic/innovative drugs during the period 2009-2015?
  • How large are these market segments in Russia? Ukraine? Kazakhstan?
  • Which countries will experience the quickest rates of growth in the generic/innovative drug sector between 2013-2015?
  • How do consumers and physicians view generic/innovative drugs in CIS countries?
  • How are the prices of both reimbursed and non-reimbursed generic/innovative drugs regulated in CIS countries?
  • What are the specific reimbursement processes in place in each CIS country?
  • What changes are in store for these drug markets and for reimbursement systems in the next few years?
  • Which recent regulatory adjustments have altered market conditions?
  • What are the latest additions and eliminations from the reimbursement lists of each highlighted country?
  • How long are drug patents viable under the laws of each CIS country?
  • What are the data exclusivity periods for generic/innovative drug products in CIS countries?
  • Which generic/innovative drugs post the highest sales in this region?
  • Which companies manufacture the greatest quantities of generic and innovative drugs within the CIS region? In each specific country?

 

Selected companies analysed in this report

AstraZeneca, Bayer, Berlin-Chemie/Menarini, Dr. Reddy’s, Egis, Farmak, Gedeon Richter, GSK, Krka, Novartis, Nycomed/Takeda, Pfizer, Pharmstandard, Ranbaxy/Daiichi Sankyo, Roche, Sanofi, Servier, Stada, Teva, Veropharm.

 

This report provides the specific, reliable market information required by

  • Companies engaged in the production and distribution of generic/innovative drugs and treatments in CIS countries
  • Businesses building a strategy for entry into this market
  • Financial service providers engaged in the banking, investment, brokerage and private equity sectors
  • Business consulting, market research and analysis service providers
  • Organisations engaged in the promotion of pharma-related industry, trade and commerce in CIS countries
  • Research, academic and governmental entities with interests in this market.

 

Convenient availability of data and analysis aids in

  • Setup of operations in the generic and/or innovative drug segments in the CIS region or specific countries
  • Assembling a diverse product portfolio
  • Comparing the regulatory frameworks of CIS countries with regard to generic and/or innovative drugs and treatments
  • Keeping current with changing drug lists – reimbursement and vital and essential – in each CIS country
  • Assessing the possibilities for growth in these market segments across the CIS region and in specific countries
  • Compiling forecasts for market conditions in the innovative and generic drug segments in CIS countries for the coming years.

 

Extract from this report

  • If the CIS region is taken into consideration, Russia accounted for almost 77% in terms of value of the generic drug subgroup in 2012. The share was close to 80% in 2011, but there was a reduction in the figure after the lowest rate of growth of the generic market among the CIS countries analysed.
  • In 2012 growth on the generic drug market in Russia fell short of that of previous years, because of the limited growth in disposable income in 2011-2012, along with low inflation and a slowdown of the overall economy.

 

Market commentary by expert

We forecast that Kazakhstan, where the pharmaceutical market is less well-developed than those of Russia and Ukraine, will experience the highest growth rates for both generic and innovative medicines for 2013-2015. Healthy growth is also expected in the Russian and Ukrainian generic markets. A double-digit figure CAGR for 2013-2015 is also forecast in the innovative drug category. This subgroup will develop more slowly than any other in Russia.

 

Agnieszka Skonieczna, Senior Pharma market Analyst

 

PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales. Market Analyst, Alpha Cement
We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis. General Manager, Sanofi-Synthelabo
PMR provides a good service and is always open to discussion. All reports are well structured & are always on time. Member of the Managment Board, SCA Hygiene Products
As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding. Development Manager, GVA Grimley
We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis. Senior Trade and Investment Adviser, British Embassy in Warsaw
PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. Senior Trade and Investment Adviser, British Embassy in Warsaw
Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. General Manager, Sanofi-Synthelabo
It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner. Business Analyst, Hilti Distribution, Russia

  1. Methodology p. 13

  2. Executive summary p. 19

  3. Characteristics of generic and innovative drug markets in Russia, Ukraine and Kazakhstan p. 25

    • Comparative analysis p. 25
      • Share of Russia, Ukraine and Kazakhstan as a proportion of generic and innovative drug subgroups in CIS  p. 25
      • Share of generic and innovative medicines as a proportion of the pharmaceutical market p. 26
      • CAGR for generic and innovative medicines for 2013-2015 p. 27
      • Market value of generic and innovative medicines in CIS between 2011 and 2015 p. 28
      • Reimbursement and pricing policies p. 29
      • Key manufacturers and best-selling medicines p. 30
      • Drug patent expiry and data exclusivity periods p. 30
      • GMP standards p. 30
    • Russia p. 31
      • Main past trends and events on generic and innovative drug market      31
      • Main anticipated trends and events on generic and innovative drug market p. 34
      • Share of pharmaceutical market p. 38
      • Market value and forecasts 2009-2015 p. 40
    • Ukraine p. 42
      • Main past trends and events on generic and innovative drug market p. 42
      • Main anticipated trends and events on generic and innovative drug market p. 45
      • Share of pharmaceutical market p. 48
      • Market value and forecasts 2009-2015 p. 49
    • Kazakhstan p. 53
      • Main trends and events on generic and innovative drug market p. 53
      • Share of pharmaceutical market p. 54
      • Market value and forecasts 2009-2015 p. 56
  4. Drug patent expiry and data exclusivity periods in CIS p. 59

    • Russia p. 59
      • Drug patent expiry p. 59
      • Data exclusivity periods p. 60
    • Ukraine p. 60
      • Drug patent expiry p. 60
      • Data exclusivity periods p. 60
    • Kazakhstan p. 61
      • Drug patent expiry p. 61
      • Data exclusivity periods p. 61
  5. Best-selling drugs in CIS countries p. 63

    • Russia p. 63
      • Pharmacy subgroup p. 63
      • Hospital subgroup p. 64
      • Reimbursement subgroup p. 65
    • Ukraine p. 65
      • Pharmacy subgroup p. 65
      • Hospital subgroup p. 66
    • Kazakhstan p. 66
      • Pharmacy subgroup p. 66
      • Hospital subgroup p. 67
  6. Counterfeit medicines in CIS p. 69

    • Russia p.   69
      • Market size p. 69
      • Categories of counterfeit drugs p.   70
      • Legal environment p. 71
    • Ukraine p. 71
      • Market size p. 71
      • Categories of counterfeit drugs p.   72
      • Legal environment p. 72
    • Kazakhstan p. 73
      • Market size p. 73
      • Categories of counterfeit drugs p.   73
      • Legal environment p. 73
  7. Reimbursement and pricing policies in Russia, Ukraine and Kazakhstan p. 75

    • Russia p. 75
      • Pricing policy p. 75
        • VAT p. 75
        • Non-essential drugs p. 75
        • Vital and essential drugs p. 76
        • Drugs on the hospital market p. 79
      • Reimbursement policies p. 80
        • Reimbursement system p. 80
        • Market structure p. 81
          • Top INN names p. 81
          • Top ATC categories p. 82
          • Share of ZHNVLP and non-ZHNVLP drugs p. 83
        • Reimbursement process p. 84
        • Latest changes to ZHNVLP lists p. 86
        • Rare diseases p. 87
        • Reimbursement spending p. 88
          • Seven disease categories programme (VZN or 7 categories) p. 88
    • Ukraine p.   89
      • Pricing policy p. 89
        • VAT p. 89
        • Drugs on the pharmacy market p. 89
        • Essential medicines and minimum mandatory range p. 92
          • Market structure p. 92
          • Prices p. 93
          • Markups p.   94
        • Drugs on the hospital market p. 95
          • Market structure p. 95
          • Prices p. 95
      • Reimbursement policies p. 97
        • Reimbursement system p. 97
        • Latest changes to reimbursed drug lists p. 98
    • Kazakhstan p. 98
      • Pricing policy p. 98
        • VAT p. 98
        • Drugs on the pharmacy market p. 98
        • Drugs on the hospital market p. 99
        • Essential medicines p. 100
      • Reimbursement policy p.   100
        • Reimbursement system p. 100
        • Reimbursement process p. 101
        • Latest changes to the reimbursed drug lists p. 101
  8. Key manufacturers in CIS countries p.   103

    • Key players in Russia p. 103
      • Total market p. 103
      • Pharmacy subgroup p. 104
      • Reimbursement subgroup p. 104
      • Hospital subgroup p. 105
      • Oncology subgroup p. 106
      • Major events and trends associated with generic and innovative manufacturers p. 107
        • Investments in production p. 107
        • Product development p.   110
        • Acquisition of companies/companies’ portfolios p. 111
    • Key players in Ukraine p.   112
      • Pharmacy subgroup p. 112
      • Hospital subgroup p. 113
      • Major events and trends associated with generic and innovative manufacturers p. 114
        • Investments in production p. 114
        • Acquisition of companies/companies’ portfolios p.   114
    • Key players in Kazakhstan p. 115
      • Pharmacy subgroup p. 115
      • Hospital subgroup p. 116
      • Major events and trends associated with generic and innovative manufacturers p. 116
        • Acquisition of companies/companies’ portfolios p.   116
        • Investments in production p. 117
    • Profiles of selected leading innovative drug manufacturers p. 118
    • Profiles of selected leading generic drug manufacturers p. 137
  9. List of graphs p. 159

  10. List of tables p. 163

  11. About PMR p. 167

List of graphs

  1. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2011-2015      20
  2. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2011-2015      20
  3. Share of specific countries as a proportion of the generic drug market in CIS countries (%), by value, 2011-2012      25
  4. Share of specific countries as a proportion of the innovative drug market in CIS countries (%), by value, 2011-2012      26
  5. Share of generic drugs as a proportion of the pharmaceutical markets in CIS countries (%), by value, 2012      26
  6. Share of innovative drugs as a proportion of the pharmaceutical markets in CIS countries (%), by value, 2012      27
  7. CAGR for innovative and generic medicines in CIS countries analysed (%), 2013-2015      27
  8. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2011-2015      28
  9. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2011-2015      28
  10. Number of clinical trials approved in Russia (%), by type, 2012      31
  11. Number of clinical trials approved in Russia (%), by phase, 2012       32
  12. Shares of generic and innovative drugs as a proportion of the pharmacy market in Russia (%), by value, 2012      39
  13. Shares of generic and innovative drugs as a proportion of the hospital market in Russia (%), by value, 2012      39
  14. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Russia (%), by value, 2012      40
  15. Value (RUB bn) and y-o-y change (%) of the Russian generic drug market, 2011-2015      41
  16. Value (RUB bn) and y-o-y change (%) of the Russian innovative drug market, 2011-2015      41
  17. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by value, 2012      48
  18. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by value, 2012      48
  19. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Ukraine (%), by value, 2012      49
  20. Change in sales volume of generic and innovative medicines in Ukraine (%, y-o-y), pharmacy market, 2011-2012      49
  21. Change in sales value of generic and innovative medicines in Ukraine (%, y-o-y), pharmacy market, 2011-2012      50
  22. Value (UAH bn) and y-o-y change (%) of the Ukrainian generic drug market, 2009-2015      51
  23. Value (UAH bn) and y-o-y change (%) of the Ukrainian innovative drug market, 2009-2015      52
  24. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by value, 2012      55
  25. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by value, 2012      55
  26. Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Ukraine (%), by value, 2012      55
  27. Value (KZT bn) and y-o-y change (%) of the Kazakh generic drug market, 2011-2015      56
  28. Value (KZT bn) and y-o-y change (%) of the Kazakh innovative drug market, 2011-2015      57
  29. Breakdown of prices of vital and essential drugs in Russia, 2013      77
  30. Drug price breakdown in the ZHNVLP subgroup in Russia, by value, H1 2011-H1 2012      78
  31. Drug price breakdown in the ZHNVLP subgroup in Russia, by volume, H1 2011-H1 2012      79
  32. Average price per packet of medicine in the hospital drug subgroup in Russia ($) and change (%), 2010 – Q1-Q3 2012      80
  33. Drug supply state funding system in Russia, 2013      80
  34. Share of ZHNVLP and non-ZHNVLP as a proportion of the Russian pharmaceutical market (%), by value, 2010-2012      83
  35. Share of ZHNVLP and non-ZHNVLP as a proportion of specific subgroups of the Russian pharmaceutical market (%), by value, 2012      83
  36. Drug reimbursement process in Russia – placing of drugs on the DLO list, 2013      84
  37. Drug reimbursement process in Russia – drug provision within the DLO subgroup, 2013      85
  38. Number and y-o-y change (%) of INNs on the ZHNVLP list in Russia, 2009-2013      86
  39. Origin of medicines on the ZHNVLP lists in Russia (%), 2012-2013      86
  40. Value (RUB bn) and volume (million packets) of the DLO subgroup in Russia, 2010-2012      88
  41. Formula for calculating the price of imported medicines which enter wholesale circulation in Ukraine, 2013      91
  42. Average pharmacy margins on medicines in Ukraine (%), 2010-2012      91
  43. Average markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), January-August 2010-2012      94
  44. Breakdown of the Ukrainian hospital market by drug price (%), by volume, H1 2012      95
  45. Breakdown of the Ukrainian hospital market by drug price (%), by value, H1 2012      96
  46. Average price per packet of medicine in Ukraine (UAH), hospital market, imported and domestic drugs, Q1-Q3 2010 – 2012      96
  47. Average price per packet of medicine in pharmacy subgroup in Kazakhstan ($) and y-o-y change (%), 2010 – Q1-Q3 2012      98
  48. Breakdown of the pharmacy market of Kazakhstan by drug price (%), by value, Q1 2012      99
  49. Average price per packet of medicine in hospital subgroup in Kazakhstan ($) and y-o-y change (%), 2010 – Q1-Q3 2012      100
  50. Dr. Reddy’s sales revenues (€ m) and y-o-y change (%) in Russia, FY 2005 – Q1-Q3 FY 2013      138
  51. Share of individual countries as a proportion of Egis’ revenues in the CIS region (%), 2009/2010-Q1 2012/2013      140
  52. Farmak net sales revenue ($ m) and y-o-y change (%), 2009-2013      141
  53. Share of individual countries as a proportion of Gedeon Richter female healthcare product sales value in CIS countries (%), 2012      143
  54. Breakdown of Pharmstandard sales (%), by category 2012      147
  55. Ranbaxy sales in Russia and Ukraine (€ m) and y-o-y change (%), 2008-2012      151

List of tables

  1. Annual average exchange rates used in this report (€ to national currency), 2010-2012      15
  2. Comparison of VAT rates, drug price controls, reimbursement solutions, patent protection and future developments for reimbursement system in CIS countries analysed, 2013      29
  3. Drug patent expiry and data exclusivity periods in CIS countries analysed in comparison with EU, 2013      30
  4. Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, essential medicines supply, 2012-2025      37
  5. Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, mortality rates, 2012-2020      37
  6. Basic sales indicators for hypertensive medicines included in the pilot reimbursement project in Ukraine, 2011-2012      44
  7. Top 10 best-selling innovative and generic drugs in Russia, by value, pharmacy subgroup, 2012      64
  8. Top 10 best-selling innovative and generic drugs in Russia, by value, hospital subgroup, Q1-Q3 2012      64
  9. Top 10 best-selling innovative and generic drugs in Russia, by value, reimbursement subgroup, Q1-Q3 2012      65
  10. Top 10 best-selling innovative and generic drugs in Ukraine, by value, pharmacy market 2012      65
  11. Top 20 best-selling generic and innovative drugs in Ukraine, by value, hospital subgroup, 2012      66
  12. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, pharmacy subgroup, Q1-Q3 2012      67
  13. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, hospital subgroup, Q1-Q3 2012      67
  14. Number of drug brand names and drug series of counterfeit medicines withdrawn from the Russian pharmaceutical market, 2005 – Q1-Q3 2012      70
  15. Top 10 INNs in the DLO subgroup in Russia, by value, Q1-Q3 2012      81
  16. Top 20 INNs of the ZHNVLP subgroup in Russia, by value, Q1 2012      81
  17. Top 20 INNs of the ZHNVLP subgroup in Russia, by volume, Q1 2012      82
  18. Top 10 ATC categories in the DLO subgroup in Russia, by value, Q1-Q3 2012      82
  19. List of life-threatening and chronic progressive rare (orphan) diseases in Russia, 2013      87
  20. Breakdown of the Ukrainian pharmacy market by drug price, by volume, 2012      90
  21. Breakdown of the Ukrainian pharmacy market by drug price, by value, 2012      90
  22. Average price per packet of medicine in Ukraine (UAH), pharmacy market, imported and domestic drugs, 2012      90
  23. Breakdown of the Ukrainian pharmacy market by imported and domestic drugs, by price range, 2010-2012      90
  24. Share of medicines on List of Essential Medicines and in mandatory minimum range as a proportion of the Ukrainian pharmacy market (%), January-August 2010-2012      92
  25. Share of imported and local medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), pharmacy market, January-August 2010-2012      93
  26. Market share of medicines on List of Essential Medicines and in mandatory minimum range in Ukraine by value and volume (%), by price range, January-August 2012      93
  27. Market share of imported and domestic medicines on List of Essential Medicines and in mandatory minimum range in Ukraine, by value and volume (%), by price range, January-August 2012      93
  28. Maximum retail markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine (%), 2013      94
  29. Average markups for medicines on List of Essential Medicines and in mandatory minimum range in Ukraine, by price range (%), January-August 2010-2012      95
  30. Top 10 generic and innovative pharmaceutical domestic manufacturers in Russia, by value, Q1-Q3 2012      103
  31. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy subgroup, 2012      104
  32. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, reimbursement subgroup, Q1-Q3 2012      104
  33. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, hospital subgroup, Q1-Q3 2012      105
  34. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by value, hospital subgroup, Q1-Q3 2012      105
  35. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by value, oncology subgroup, Q1-Q3 2012      106
  36. Top 10 generic and innovative domestic pharmaceutical manufacturers in Russia, by volume, oncology subgroup, Q1-Q3 2012      106
  37. Selected completed investments in pharmaceutical production in Russia, 2011-Q1 2013      107
  38. Selected planned investments in pharmaceutical production in Russia, 2013-2017      108-109
  39. Selected agreements pertaining to new product development in Russia, 2012-Q1 2013      110
  40. Selected pharmaceutical companies acquired in Russia, 2012-Q1 2013      111
  41. Top generic pharmaceutical manufacturers in Ukraine, by value, pharmacy subgroup, 2012      112
  42. Top innovative pharmaceutical manufacturers in Ukraine, by value, pharmacy subgroup, 2012      112
  43. Top generic pharmaceutical manufacturers in Ukraine, by value, hospital subgroup, Q1-Q3 2012      113
  44. Top innovative pharmaceutical manufacturers in Ukraine, by value, hospital subgroup, Q1-Q3 2012      113
  45. Acquisition of selected pharmaceutical companies in Ukraine, 2012-Q1 2013      115
  46. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, pharmacy subgroup, Q1-Q3 2012      115
  47. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, hospital subgroup, Q1-Q3 2012      116
  48. Acquisition of selected pharmaceutical companies in Kazakhstan, 2012-Q1 2013      116
  49. Selected planned investments in pharmaceutical production in Kazakhstan, 2013-2016      117
  50. Bayer pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      118
  51. Bayer’s clinical trials carried out in CIS countries analysed, March 2013      119
  52. GSK pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      119
  53. GlaxoSmithKline’s clinical trials carried out in CIS countries analysed, March 2013      121
  54. Novartis pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      122
  55. Novartis’ clinical trials carried out in CIS countries analysed, March 2013      123
  56. Nycomed/Takeda pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      124
  57. Takeda, selected business partners and their products in Takeda’s portfolio in CIS countries, 2013      125-126
  58. Takeda clinical trials carried out in CIS countries analysed, March 2013      127
  59. Pfizer pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      128
  60. Pfizer’s clinical trials carried out in CIS countries analysed, March 2013      129
  61. Roche’s clinical trials carried out in CIS countries analysed, March 2013      131
  62. Sanofi pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      132
  63. Sanofi’s clinical trials carried out in CIS countries analysed, March 2013      135
  64. Servier pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      135
  65. Berlin-Chemie/Menarini pharmacy sales in selected CIS countries (€ m) and y-o-y change (%), 2010-2012      137
  66. Sales value ($ m) and growth (%) of selected Dr. Reddy’s brands in Russia, FY 2011-2012      139
  67. Egis sales in individual CIS countries (€ m) and y-o-y change (%), 2008/2009-Q1 2012/2013      139
  68. Gedeon Richter sales in individual CIS countries (€ m) and y-o-y change (%), 2007-2012      142
  69. Products launched by Gedeon Richter in CIS countries, 2012      143
  70. Krka sales in selected CIS countries (€ m) and y-o-y change (%), 2007-2012      145
  71. Selected products launched by Krka in CIS countries, Q1-Q3 2012      145
  72. Pharmstandard sales in individual CIS countries (€ m) and y-o-y change (%), 2009-2012      147
  73. Pharmstandard’s best-selling own Rx generic and innovative drugs in the CIS, by value, 2012      149
  74. New products due to be introduced on the market by Pharmstandard, 2013      150
  75. New generics products due to be introduced on the market by Pharmstandard, 2013      150
  76. Ranbaxy/Daiichi’s clinical trials carried out in CIS countries analysed, March 2013      153
  77. Stada sales of generic and branded products in Russia (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012      153
  78. Stada sales of generic and branded products in Ukraine (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012      153
  79. Stada sales of generic and branded products in Kazakhstan (€ m) and y-o-y change (%), 2008 – Q1-Q3 2012      154
  80. Teva sales in individual CIS countries (€ m) and y-o-y change (%), 2010-2012      156
  81. Teva’s clinical trials carried out in CIS countries analysed, March 2013      157